Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers

References

• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761–774. doi:10.1038/nrc3106
   PubMed Web of Science ®Google Scholar
• Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19(49):5636–5642. doi:10.1038/sj.onc.1203912
   PubMed Web of Science ®Google Scholar
• Chakraborty AA, Scuoppo C, Dey S, et al. A common functional consequence of tumor-derived mutations within c-MYC. Oncogene. 2015;34(18):2406–2409. doi:10.1038/onc.2014.186
   PubMed Web of Science ®Google Scholar
• Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. 1911;13(4):397–411. doi:10.1084/jem.13.4.397
   PubMedGoogle Scholar
• Mladenov Z, Heine U, Beard D, Beard JW. Strain MC29 avian leukosis virus. Myelocytoma, endothelioma, and renal growths: pathomorphological and ultrastructural aspects. J Natl Cancer Inst. 1967;38(3):251–285.
   PubMedGoogle Scholar
• Vennstrom B, Sheiness D, Zabielski J, Bishop JM. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol. 1982;42(3):773–779. doi:10.1128/JVI.42.3.773-779.1982
   PubMed Web of Science ®Google Scholar
• Sheiness D, Bishop JM. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol. 1979;31(2):514–521. doi:10.1128/JVI.31.2.514-521.1979
   PubMed Web of Science ®Google Scholar
• Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 1993;7(4):671–682. doi:10.1101/gad.7.4.671
   PubMed Web of Science ®Google Scholar
• de Alboran IM, O’Hagan RC, Gartner F, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001;14(1):45–55. doi:10.1016/s1074-7613(01)00088-7
   PubMed Web of Science ®Google Scholar
• Rabbitts PH, Watson JV, Lamond A, et al. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J. 1985;4(8):2009–2015. doi:10.1002/j.1460-2075.1985.tb03885.x
   PubMed Web of Science ®Google Scholar
• Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–1133. doi:10.1038/ng.2762
   PubMed Web of Science ®Google Scholar
• Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4(6):a014241–a014241. doi:10.1101/cshperspect.a014241
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–990. doi:10.1038/nrc2231
   PubMed Web of Science ®Google Scholar
• Xu L, Morgenbesser SD, DePinho RA. Complex transcriptional regulation of myc family gene expression in the developing mouse brain and liver. Mol Cell Biol. 1991;11(12):6007–6015. doi:10.1128/mcb.11.12.6007-6015.1991
   PubMed Web of Science ®Google Scholar
• Bull JJ, Muller-Rover S, Patel SV, Chronnell CM, McKay IA, Philpott MP. Contrasting localization of c-Myc with other Myc superfamily transcription factors in the human hair follicle and during the hair growth cycle. J Invest Dermatol. 2001;116(4):617–622. doi:10.1046/j.1523-1747.2001.12771234.x
   PubMed Web of Science ®Google Scholar
• Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–264. doi:10.1016/j.semcancer.2006.07.014
   PubMed Web of Science ®Google Scholar
• Kalkat M, De Melo J, Hickman KA, et al. MYC deregulation in primary human cancers. Genes. 2017;8(6):151. doi:10.3390/genes8060151
   PubMed Web of Science ®Google Scholar
• Sabo A, Kress TR, Pelizzola M, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014;511(7510):488–492. doi:10.1038/nature13537
   PubMed Web of Science ®Google Scholar
• Walz S, Lorenzin F, Morton J, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014;511(7510):483–487. doi:10.1038/nature13473
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154. doi:10.1016/j.ctrv.2021.102154
   PubMed Web of Science ®Google Scholar
• Schuster C, Berger A, Hoelzl MA, et al. The cooperating mutation or “second hit” determines the immunologic visibility toward MYC-induced murine lymphomas. Blood. 2011;118(17):4635–4645. doi:10.1182/blood-2010-10-313098
   PubMed Web of Science ®Google Scholar
• Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18(20):5546–5553. doi:10.1158/1078-0432.CCR-12-0977
   PubMed Web of Science ®Google Scholar
• Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - The grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23–36. doi:10.1038/s41571-021-00549-2
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905. doi:10.1038/nature08822
   PubMed Web of Science ®Google Scholar
• Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20(40):5595–5610. doi:10.1038/sj.onc.1204595
   PubMed Web of Science ®Google Scholar
• Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. Med J Aust. 2019;210(8):375–380. doi:10.5694/mja2.50129
   PubMed Web of Science ®Google Scholar
• Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair. 2006;5(9–10):1213–1224. doi:10.1016/j.dnarep.2006.05.017
   PubMed Web of Science ®Google Scholar
• Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580–5594. doi:10.1038/sj.onc.1204640
   PubMed Web of Science ®Google Scholar
• Erikson J, Finger L, Sun L, et al. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science. 1986;232(4752):884–886. doi:10.1126/science.3486470
   PubMed Web of Science ®Google Scholar
• Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16(11):2985–2995. doi:10.1093/emboj/16.11.2985
   PubMed Web of Science ®Google Scholar
• Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer. 2021;20(1):3. doi:10.1186/s12943-020-01291-6
   PubMed Web of Science ®Google Scholar
• Dudley JP, Mertz JA, Rajan L, Lozano M, Broussard DR. What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia. 2002;16(6):1086–1098. doi:10.1038/sj.leu.2402451
   PubMed Web of Science ®Google Scholar
• Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999;3(2):169–179. doi:10.1016/s1097-2765(00)80308-1
   PubMed Web of Science ®Google Scholar
• He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–1512. doi:10.1126/science.281.5382.1509
   PubMed Web of Science ®Google Scholar
• Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103(48):18261–18266. doi:10.1073/pnas.0606108103
   PubMed Web of Science ®Google Scholar
• Farrell AS, Joly MM, Allen-Petersen BL, et al. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun. 2017;8(1):1728. doi:10.1038/s41467-017-01967-6
   PubMedGoogle Scholar
• Ruvolo PP. The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 2016;6:87–99. doi:10.1016/j.bbacli.2016.08.002
   PubMedGoogle Scholar
• Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 1999;18(3):717–726. doi:10.1093/emboj/18.3.717
   PubMed Web of Science ®Google Scholar
• Luscher B, Larsson LG. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene. 1999;18(19):2955–2966. doi:10.1038/sj.onc.1202750
   PubMed Web of Science ®Google Scholar
• Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991;251(4998):1211–1217. doi:10.1126/science.2006410
   PubMed Web of Science ®Google Scholar
• Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008;22(20):2755–2766. doi:10.1101/gad.1712408
   PubMed Web of Science ®Google Scholar
• Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999;18(19):2916–2924. doi:10.1038/sj.onc.1202748
   PubMed Web of Science ®Google Scholar
• Herkert B, Eilers M. Transcriptional repression: the dark side of myc. Genes Cancer. 2010;1(6):580–586. doi:10.1177/1947601910379012
   PubMedGoogle Scholar
• Scafuro M, Capasso L, Carafa V, Altucci L, Nebbioso A. Gene transactivation and transrepression in MYC-driven cancers. Int J Mol Sci. 2021;22(7):3458. doi:10.3390/ijms22073458
   PubMed Web of Science ®Google Scholar
• Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A. 2000;97(5):2229–2234. doi:10.1073/pnas.050586197
   PubMed Web of Science ®Google Scholar
• Yang W, Shen J, Wu M, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20(14):1688–1702. doi:10.1038/sj.onc.1204245
   PubMed Web of Science ®Google Scholar
• Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J. Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol. 2000;20(10):3497–3509. doi:10.1128/MCB.20.10.3497-3509.2000
   PubMed Web of Science ®Google Scholar
• Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. Drosophila myc regulates cellular growth during development. Cell. 1999;98(6):779–790. doi:10.1016/s0092-8674(00)81512-3
   PubMed Web of Science ®Google Scholar
• Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11–21. doi:10.1016/j.semcdb.2015.08.003
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, Schmidt EV. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci U S A. 1993;90(13):6175–6178. doi:10.1073/pnas.90.13.6175
   PubMed Web of Science ®Google Scholar
• Gomez-Roman N, Grandori C, Eisenman RN, White RJ. Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003;421(6920):290–294. doi:10.1038/nature01327
   PubMed Web of Science ®Google Scholar
• Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019;20(7):436–450. doi:10.1038/s41580-019-0123-5
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364–368. doi:10.1038/nature08697
   PubMed Web of Science ®Google Scholar
• Morrish F, Noonan J, Perez-Olsen C, et al. Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J Biol Chem. 2010;285(47):36267–36274. doi:10.1074/jbc.M110.141606
   PubMed Web of Science ®Google Scholar
• D’Avola A, Legrave N, Tajan M, et al. PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma. J Clin Invest. 2022;132(9). doi:10.1172/JCI153436
   PubMed Web of Science ®Google Scholar
• Bott AJ, Peng IC, Fan Y, et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 2015;22(6):1068–1077. doi:10.1016/j.cmet.2015.09.025
   PubMed Web of Science ®Google Scholar
• Schuhmacher M, Staege MS, Pajic A, et al. Control of cell growth by c-Myc in the absence of cell division. Curr Biol. 1999;9(21):1255–1258. doi:10.1016/s0960-9822(99)80507-7
   PubMed Web of Science ®Google Scholar
• Bacon TA, Wickstrom E. Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media. Oncogene Res. 1991;6(1):21–32.
   PubMedGoogle Scholar
• Lin KI, Lin Y, Calame K. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol. 2000;20(23):8684–8695. doi:10.1128/MCB.20.23.8684-8695.2000
   PubMed Web of Science ®Google Scholar
• Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer. 2008;8(1):51–56. doi:10.1038/nrc2274
   PubMed Web of Science ®Google Scholar
• Gandarillas A, Watt FM. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev. 1997;11(21):2869–2882. doi:10.1101/gad.11.21.2869
   PubMed Web of Science ®Google Scholar
• Laurenti E, Varnum-Finney B, Wilson A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell. 2008;3(6):611–624. doi:10.1016/j.stem.2008.09.005
   PubMed Web of Science ®Google Scholar
• Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21(15):5063–5070. doi:10.1128/MCB.21.15.5063-5070.2001
   PubMed Web of Science ®Google Scholar
• Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: marvelouslY complex. Adv Cancer Res. 2002;84:81–154. doi:10.1016/s0065-230x(02)84004-0
   PubMed Web of Science ®Google Scholar
• Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436(7052):807–811. doi:10.1038/nature03845
   PubMed Web of Science ®Google Scholar
• Meskyte EM, Keskas S, Ciribilli Y. MYC as a multifaceted regulator of tumor microenvironment leading to metastasis. Int J Mol Sci. 2020;21(20):7710. doi:10.3390/ijms21207710
   PubMed Web of Science ®Google Scholar
• Sun L, Wang Q, Chen B, et al. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell Death Dis. 2018;9(9):928. doi:10.1038/s41419-018-0988-9
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227–231. doi:10.1126/science.aac9935
   PubMed Web of Science ®Google Scholar
• Kharma B, Baba T, Matsumura N, et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res. 2014;74(22):6519–6530. doi:10.1158/0008-5472.CAN-14-0847
   PubMed Web of Science ®Google Scholar
• Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell. 1986;47(5):667–674. doi:10.1016/0092-8674(86)90509-x
   PubMed Web of Science ®Google Scholar
• Braun J, Felsher DW, Goodglick LA. c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. Ann N Y Acad Sci. 1992;651:467–469. doi:10.1111/j.1749-6632.1992.tb24647.x
   PubMed Web of Science ®Google Scholar
• Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI. c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 1988;7(4):1023–1029. doi:10.1002/j.1460-2075.1988.tb02909.x
   PubMed Web of Science ®Google Scholar
• Whitfield JR, Soucek L. The long journey to bring a Myc inhibitor to the clinic. J Cell Biol. 2021;220(8). doi:10.1083/jcb.202103090
   PubMed Web of Science ®Google Scholar
• McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med. 2014;4(10):a014266–a014266. doi:10.1101/cshperspect.a014266
   PubMed Web of Science ®Google Scholar
• Donati G, Amati B. MYC and therapy resistance in cancer: risks and opportunities. Mol Oncol. 2022;16(21):3828–3854. doi:10.1002/1878-0261.13319
   PubMed Web of Science ®Google Scholar
• Bahls B, Aljnadi IM, Emídio R, Mendes E, Paulo A. G-quadruplexes in c-MYC promoter as targets for cancer therapy. Biomedicines. 2023;11(3):969. doi:10.3390/biomedicines11030969
   PubMed Web of Science ®Google Scholar
• Ohanian M, Arellano ML, Levy MY, et al. A Phase 1a/b dose escalation study of the MYC repressor Apto-253 in patients with relapsed or refractory AML or high-risk MDS. presented at: American Society of Hematology Annual Meeting; 2021.
   Google Scholar
• Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28(8):1776–1787. doi:10.1093/annonc/mdx157
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang J, Yin J, et al. Alternative approaches to target Myc for cancer treatment. Signal Transduct Target Ther. 2021;6(1):117. doi:10.1038/s41392-021-00500-y
   PubMed Web of Science ®Google Scholar
• Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol. 2017;5:10. doi:10.3389/fcell.2017.00010
   PubMed Web of Science ®Google Scholar
• Huang HL, Weng HY, Wang LQ, et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 2012;11(5):1155–1165. doi:10.1158/1535-7163.MCT-12-0066
   PubMed Web of Science ®Google Scholar
• Otto T, Horn S, Brockmann M, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15(1):67–78. doi:10.1016/j.ccr.2008.12.005
   PubMed Web of Science ®Google Scholar
• Riches JC, Gribben JG. Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Curr Cancer Drug Targets. 2016;16(8):689–700. doi:10.2174/1568009616666160408145741
   PubMed Web of Science ®Google Scholar
• Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998;17(19):2463–2472. doi:10.1038/sj.onc.1202199
   PubMed Web of Science ®Google Scholar
• Toyoshima M, Howie HL, Imakura M, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A. 2012;109(24):9545–9550. doi:10.1073/pnas.1121119109
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu ZZ, Aoshima K, et al. CECR2 drives breast cancer metastasis by promoting NF-kappaB signaling and macrophage-mediated immune suppression. Sci Transl Med. 2022;14(630):eabf5473. doi:10.1126/scitranslmed.abf5473
   PubMed Web of Science ®Google Scholar
• Liu L, Ulbrich J, Muller J, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature. 2012;483(7391):608–612. doi:10.1038/nature10927
   PubMed Web of Science ®Google Scholar
• Kelly GL, Grabow S, Glaser SP, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014;28(1):58–70. doi:10.1101/gad.232009.113
   PubMed Web of Science ®Google Scholar
• Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell. 2004;5(5):501–512. doi:10.1016/s1535-6108(04)00113-8
   PubMed Web of Science ®Google Scholar
• Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007;13(7):820–827. doi:10.1038/nm1606
   PubMed Web of Science ®Google Scholar
• Huang CH, Lujambio A, Zuber J, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014;28(16):1800–1814. doi:10.1101/gad.244368.114
   PubMed Web of Science ®Google Scholar
• Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126–1139. doi:10.1016/j.cell.2014.10.024
   PubMed Web of Science ®Google Scholar
• Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616–620. doi:10.1038/nature13393
   PubMed Web of Science ®Google Scholar
• Horiuchi D, Camarda R, Zhou AY, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016;22(11):1321–1329. doi:10.1038/nm.4213
   PubMed Web of Science ®Google Scholar
• Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012;335(6066):348–353. doi:10.1126/science.1212728
   PubMed Web of Science ®Google Scholar
• Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178(1):93–105. doi:10.1083/jcb.200703099
   PubMed Web of Science ®Google Scholar
• Yuneva MO, Fan TW, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157–170. doi:10.1016/j.cmet.2011.12.015
   PubMed Web of Science ®Google Scholar
• Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:369–374. doi:10.1101/sqb.2011.76.011296
   PubMedGoogle Scholar
• Le A, Lane AN, Hamaker M, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–121. doi:10.1016/j.cmet.2011.12.009
   PubMed Web of Science ®Google Scholar
• Mendez-Lucas A, Lin W, Driscoll PC, et al. Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020;2(4):335–350. doi:10.1038/s42255-020-0195-8
   PubMedGoogle Scholar
• Edwards-Hicks J, Su H, Mangolini M, et al. MYC sensitises cells to apoptosis by driving energetic demand. Nat Commun. 2022;13(1):4674. doi:10.1038/s41467-022-32368-z
   PubMed Web of Science ®Google Scholar
• Wilke AC, Doebele C, Zindel A, et al. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2022;139(4):538–553. doi:10.1182/blood.2021012081
   PubMed Web of Science ®Google Scholar
• Krysov S, Dias S, Paterson A, et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012;119(1):170–179. doi:10.1182/blood-2011-07-370403
   PubMed Web of Science ®Google Scholar
• Kluckova K, Clear AJ, D’Avola A, et al. B-cell receptor signaling induced metabolic alterations in chronic lymphocytic leukemia can be partially bypassed by TP53 Abnormalities. Hemasphere. 2022;6(6):e722. doi:10.1097/HS9.0000000000000722
   PubMed Web of Science ®Google Scholar
• He TL, Zhang YJ, Jiang H, Li XH, Zhu H, Zheng KL. The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Med Oncol. 2015;32(7):187. doi:10.1007/s12032-015-0633-8
   PubMed Web of Science ®Google Scholar
• Vettraino M, Manerba M, Govoni M, Di Stefano G. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1. Anticancer Drugs. 2013;24(8):862–870. doi:10.1097/CAD.0b013e328363ae50
   PubMed Web of Science ®Google Scholar
• Doherty JR, Yang C, Scott KE, et al. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 2014;74(3):908–920. doi:10.1158/0008-5472.CAN-13-2034
   PubMed Web of Science ®Google Scholar
• Gan L, Xiu R, Ren P, et al. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters. Oncogene. 2016;35(23):3037–3048. doi:10.1038/onc.2015.360
   PubMed Web of Science ®Google Scholar
• Camarda R, Zhou AY, Kohnz RA, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22(4):427–432. doi:10.1038/nm.4055
   PubMed Web of Science ®Google Scholar
• Pacilli A, Calienni M, Margarucci S, et al. Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J Natl Cancer Inst. 2013;105(7):489–498. doi:10.1093/jnci/djt030
   PubMedGoogle Scholar
• Jia J, Che L, Cigliano A, et al. Pivotal role of fatty acid synthase in c-MYC driven hepatocarcinogenesis. Int J Mol Sci. 2020;21(22):8467. doi:10.3390/ijms21228467
   PubMed Web of Science ®Google Scholar
• Gouw AM, Margulis K, Liu NS, et al. The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth. Cell Metab. 2019;30(3):556–572 e5. doi:10.1016/j.cmet.2019.07.012
   PubMed Web of Science ®Google Scholar